Saturday 17 October 2026 Export ACB’s income statement to Excel — free account

Aurora Cannabis Inc.

ACB Healthcare Drug Manufacturers Specialty & Generic

Aurora Cannabis Inc.’s revenue for fiscal 2026 (year ended March 2026) was $232.0 million, down 5.95% from fiscal 2025. In the quarter to June 2026, revenue fell 31.2%, EPS grew 75.0%, free cash flow fell 293.6% and total debt fell 82.5%, each against the same quarter a year earlier.

3.99 0.11 −2.68%

Follow ACB

Alert me

Market cap: $265.8M
P/E: 0.0×
Fwd P/E: −783×
Dividend yield: —
F-score: 4/9
Altman Z: −12.34
Beneish M: −2.53
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 265.84

Revenue 209.97

Net Income (31.33)

Free Cash Flow (36.10)

Net Debt (95.56)

Current Ratio 5.36

Debt/Equity 0.03

P/E ratio 0.00

Fwd P/E (783.00)

P/S ratio 1.17

P/B ratio 0.65

Past 5Y EPS Growth —

This Y EPS Growth 86.29%

Next Y EPS Growth 161.44%

Next Y revenue growth (10.47%)

Next 5Y EPS Growth 27.04%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 24.63%

10-year low 10-year high

P/B against its own 10 years 36.33%

10-year low 10-year high

EV/Sales against its own 10 years 24.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	136	134	119	108
Receivables	34	31	32	30
Inventory	138	172	127	135
Other	2	0	1	2
	316	344	288	284

	2024	2025	2026	Q'26
Payables	43	53	37	41
ST’ Debt	39	15	—	—
Other	4	1	2	2
	92	80	48	53

Compound Annual Growth %

	10y	5y	3y
Sales	70.99%	3.92%	9.78%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	54.99%	(25.28%)	0.46%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	49	—
’26	66	68	28	71	232
’25	59	63	63	61	247
’24	47	47	50	—	200
’23	38	45	53	56	175
’22	48	48	40	39	175
’21	51	52	44	45	191

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(3)	—	—	—	—
’26	7	(29)	12	0	(10)
’25	6	(18)	21	3	12
’24	—	(23)	(3)	(16)	(51)
’23	(8)	(24)	(44)	—	(87)
’22	(87)	(18)	(17)	(31)	(87)
’21	(164)	(81)	(51)	(49)	(164)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(7)	—	—	—	—
’26	4	(33)	9	(4)	(25)
’25	3	(21)	18	0	(1)
’24	—	(26)	1	(20)	(54)
’23	(10)	(24)	(35)	—	(87)
’22	(97)	(16)	(26)	(23)	(97)
’21	(191)	(93)	(58)	(59)	(191)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	(0.05)	—
’26	(0.66)	0.02	(0.72)	(0.20)	(1.55)
’25	(0.16)	0.41	(0.24)	0.10	0.03
’24	(0.10)	(0.40)	(0.30)	—	(1.13)
’23	(1.30)	(1.50)	1.00	(0.60)	(0.62)
’22	(0.50)	(3.00)	(37.30)	(2.03)	(63.16)
’21	(6.90)	(13.40)	(6.70)	(0.55)	(32.08)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	162.01	468.43	225.60	37.10	53.90	8.21	4.10	2.84	3.42	2.56	Analyst estimates 2027–2029 Powerpack
	High	969.72	1,503.00	1,238.40	278.40	189.80	60.50	12.05	9.35	6.91	4.67
People
People	Employees	171	64	2,779	2,731	1,761	1,338	—	1,073	1,130	1,028
	Revenue/emp, $m	0.08	0.68	0.07	0.08	0.11	0.13	0.00	0.19	0.22	0.23
Income, $m
Income, $m	Revenue	14	43	187	208	191	175	175	200	247	232
	Gross margin, %	88.87	64.48	64.46	(12.03)	(8.79)	9.59	(27.59)	48.64	54.65	42.62
	EBT	(13)	61	(248)	(2,523)	(546)	(1,359)	(222)	(44)	15	(41)
	EBT margin, %	(95.56)	140.09	(132.38)	(1,213.27)	(285.34)	(777.14)	(126.63)	(22.05)	5.94	(17.63)
	Net income	(10)	55	(225)	(2,461)	(541)	(1,357)	(199)	(44)	11	(42)
	Depreciation	1	10	67	86	77	74	25	27	19	13
Per share, $
Per share, $	Revenue	5.86	11.35	22.13	21.49	11.32	8.14	0.54	4.64	4.50	4.09
	Earnings	(4.21)	14.24	(26.59)	(255.10)	(32.08)	(63.16)	(0.62)	(1.13)	0.03	(1.55)
	Cash flow	(3.41)	(16.80)	(17.16)	(26.04)	(9.72)	(4.04)	(0.27)	(1.17)	0.21	(0.17)
	Capex	(10.53)	(56.70)	(36.98)	(27.07)	(1.56)	(0.46)	0.00	(0.08)	(0.22)	(0.27)
	Free cash flow	(13.94)	(73.49)	(54.14)	(53.11)	(11.28)	(4.50)	(0.27)	(1.26)	(0.01)	(0.45)
	Book value	71.00	321.48	391.88	163.87	94.05	24.35	1.13	10.32	7.98	6.53
	Shares, m	2	4	8	10	17	21	323	43	55	57
Valuation, ×
Valuation, ×	P/E	0.00	1,381.62	0.00	0.00	0.00	0.00	0.00	0.00	39.91	0.00
	P/S	330.36	741.08	424.53	57.79	79.86	16.22	0.98	0.93	0.98	0.80
	P/B	27.20	26.17	23.98	7.58	9.61	5.42	0.50	0.42	0.55	0.50
	EV/Sales	324.21	742.05	425.67	59.08	79.65	15.20	0.71	0.62	0.72	0.53
	EV/FCF	0.00	(90.74)	(101.55)	(12.71)	(38.03)	(16.48)	(0.82)	(2.30)	(302.77)	(4.89)
Cash, $m
Cash, $m	Operating cash flow	(8)	(64)	(145)	(252)	(164)	(87)	(87)	(51)	12	(10)
	Capex	(24)	(217)	(313)	(262)	(26)	(10)	(9)	(3)	(12)	(16)
	Free cash flow	(32)	(281)	(458)	(514)	(191)	(97)	(87)	(54)	(1)	(25)
Balance, $m
Balance, $m	Working capital	128	114	172	110	429	474	179	224	264	239
	Total debt	48	160	487	396	307	208	171	74	71	13
	Net debt	(84)	42	214	270	(40)	(179)	(55)	(62)	(62)	(106)
	Shareholders’ equity	165	1,231	3,316	1,585	1,591	523	365	446	437	370
Returns, %
Returns, %	ROA	(6.53)	6.48	(7.76)	(79.21)	(26.41)	(93.92)	(25.69)	(7.38)	0.26	(16.82)
	ROIC	(6.47)	(4.09)	(4.20)	(12.33)	(8.90)	(33.21)	0.00	(5.60)	0.59	(7.98)
	ROE	(11.52)	8.12	(9.66)	(100.72)	(34.17)	(128.39)	(44.89)	(11.98)	0.37	(21.82)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)	Compare
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)	Compare
CGC Canopy Growth Corporation	$311.2M	— (loss-making)	— (loss-making)	+12.41% (above 0%: growing)	n/m	−117.60% (below 0%: shrinking)	27.40%	(27.24%)	Compare
ANIK Anika Therapeutics Inc.	$276.9M	— (loss-making)	— (loss-making)	+15.56% (above 0%: growing)	n/m	+61.58% (above 0%: growing)	65.15%	9.06%	Compare
ACB Aurora Cannabis Inc.	$265.8M	— (loss-making)	— (loss-making)	−31.15% (below 0%: shrinking)	n/m	−293.56% (below 0%: shrinking)	52.73%	(12.92%)
BIOA BioAge Labs, Inc.	$245.6M	— (loss-making)	— (loss-making)	+1.62% (above 0%: growing)	n/m	+2.68% (above 0%: growing)	100.00%	(1,196.78%)	Compare
LFCR Lifecore Biomedical, Inc.	$244.1M	— (loss-making)	— (loss-making)	−6.25% (below 0%: shrinking)	n/m	−117.03% (below 0%: shrinking)	35.34%	7.51%	Compare
SIGA Siga Technologies Inc.	$229.2M	— (loss-making)	28.7×	−49.45% (below 0%: shrinking)	−66.00% (below 0%: shrinking)	−75.95% (below 0%: shrinking)	57.17%	33.91%	Compare
AKBA Akebia Therapeutics, Inc.	$192.7M	— (loss-making)	— (loss-making)	−21.36% (below 0%: shrinking)	n/m	−88.99% (below 0%: shrinking)	78.78%	(12.88%)	Compare
Median of peers	$261.2M	—	—	+7.02%	—	−61.81%	57.87%	(18.30%)

All 86 Drug Manufacturers Specialty & Generic stocks →